Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.

Peter Ferenci; Thomas-Matthias Scherzer; Heidrun Kerschner; Karoline Rutter; Sandra Beinhardt; Harald Hofer; Maximilian Schöniger-Hekele; Heidemarie Holzmann; Petra Steindl-Munda

doi:10.1053/j.gastro.2008.07.072

Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.

Identifier:nobleid.org/w1/20260515/C2DFBC7F

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/C2DFBC7F.svg?ark=w1%2F20260515%2FC2DFBC7F)](https://nobleid.org/work/w1/20260515/C2DFBC7F)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Peter Ferenci

Thomas-Matthias Scherzer

Maximilian Schöniger-Hekele

Heidemarie Holzmann

Petra Steindl-Munda

Claim authorship of this work

Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.

Identifier:nobleid.org/w1/20260515/C2DFBC7F

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/C2DFBC7F.svg?ark=w1%2F20260515%2FC2DFBC7F)](https://nobleid.org/work/w1/20260515/C2DFBC7F)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Peter Ferenci

Thomas-Matthias Scherzer

Maximilian Schöniger-Hekele

Heidemarie Holzmann

Petra Steindl-Munda

Claim authorship of this work